Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 2
2004 4
2005 3
2006 6
2007 4
2008 6
2009 6
2010 10
2011 6
2012 11
2013 13
2014 11
2015 14
2016 14
2017 12
2018 17
2019 20
2020 29
2021 31
2022 26
2023 32
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M, Cuppens K, Plönes T, Wiesweg M, Du Pont B, Hegedus B, Köster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lähnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Schuler M, et al. Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965-0. Online ahead of print. Nat Med. 2024. PMID: 38689060
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, Lueong S, Metzenmacher M, Herold T, Zaun G, Laue K, Drzezga A, Theegarten D, Nensa F, Wolf J, Herrmann K, Wiesweg M. Schuler M, et al. J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979. Online ahead of print. J Nucl Med. 2024. PMID: 38575188
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M, Pöttgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, Metzenmacher M, Aigner C, Bölükbas S, Gauler T, Eberhardt WEE, Forsting M, Herrmann K, Theegarten D, Darwiche K, Jendrossek V, Stuschke M, Schuler M. Guberina M, et al. Among authors: schuler m. Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174. Cancers (Basel). 2024. PMID: 38539510 Free PMC article.
Evolutionary trajectories of small cell lung cancer under therapy.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. George J, et al. Among authors: schuler m. Nature. 2024 Mar;627(8005):880-889. doi: 10.1038/s41586-024-07177-7. Epub 2024 Mar 13. Nature. 2024. PMID: 38480884 Free PMC article.
LIONS PREY: A New Logistic Scoring System for the Prediction of Malignant Pulmonary Nodules.
Doerr F, Giese A, Höpker K, Menghesha H, Schlachtenberger G, Grapatsas K, Baldes N, Baldus CJ, Hagmeyer L, Fallouh H, Pinto Dos Santos D, Bender EM, Quaas A, Heldwein M, Wahlers T, Hautzel H, Darwiche K, Taube C, Schuler M, Hekmat K, Bölükbas S. Doerr F, et al. Among authors: schuler m. Cancers (Basel). 2024 Feb 9;16(4):729. doi: 10.3390/cancers16040729. Cancers (Basel). 2024. PMID: 38398120 Free PMC article.
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G, Borchert S, Metzenmacher M, Lueong S, Wiesweg M, Zaun Y, Pogorzelski M, Behrens F, Schildhaus HU, Virchow I, Kasper S, Schuler M, Theurer S, Liffers S. Zaun G, et al. Among authors: schuler m. Eur J Cancer. 2024 Mar;200:113540. doi: 10.1016/j.ejca.2024.113540. Epub 2024 Jan 26. Eur J Cancer. 2024. PMID: 38316065 Free article.
Postoperative Tobacco Cessation Improves Quality of Life, Lung Function and Long-Term Survival in Non-Small-Cell Lung Cancer Patients.
Doerr F, Leschczyk T, Grapatsas K, Menghesha H, Baldes N, Schlachtenberger G, Heldwein MB, Michel M, Quaas A, Hagmeyer L, Höpker K, Wahlers T, Darwiche K, Taube C, Schuler M, Hekmat K, Bölükbas S. Doerr F, et al. Among authors: schuler m. Cancers (Basel). 2024 Jan 22;16(2):465. doi: 10.3390/cancers16020465. Cancers (Basel). 2024. PMID: 38275905 Free PMC article.
Drivers and barriers of patients' acceptance of video consultation in cancer care.
Nurtsch A, Teufel M, Jahre LM, Esber A, Rausch R, Tewes M, Schöbel C, Palm S, Schuler M, Schadendorf D, Skoda EM, Bäuerle A. Nurtsch A, et al. Among authors: schuler m. Digit Health. 2024 Jan 4;10:20552076231222108. doi: 10.1177/20552076231222108. eCollection 2024 Jan-Dec. Digit Health. 2024. PMID: 38188860 Free PMC article.
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.
Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers ST, Borchert S, Costa PF, Schaarschmidt BM, Kessler L, Miera MA, Droste M, Akbulut M, Falkenhorst J, Zarrad F, Kostbade K, Mavroeidi IA, Glimm H, Umutlu L, Schuler M, Hübschmann D, Bauer S, Fröhling S, Herrmann K, Siveke JT, Schildhaus HU, Fendler WP. Hamacher R, et al. Among authors: schuler m. J Nucl Med. 2024 Feb 1;65(2):252-257. doi: 10.2967/jnumed.123.266411. J Nucl Med. 2024. PMID: 38176718
256 results